We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

179 hedge funds and large institutions have $298M invested in Aquestive Therapeutics in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 56 increasing their positions, 47 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

347% more call options, than puts

Call options by funds: $9.58M | Put options by funds: $2.14M

19% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 47

14% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 43

2% more funds holding

Funds holding: 176 → 179 (+3)

0.3% less ownership

Funds ownership: 59.11% → 58.81% (-0.3%)

36% less capital invested

Capital invested by funds: $466M → $298M (-$168M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
179
Holders Change
+3
Holders Change %
+1.7%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
49
Increased
56
Reduced
47
Closed
43
Calls
$9.58M
Puts
$2.14M
Net Calls
+$7.44M
Net Calls Change
+$6.16M

Top Buyers

1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$7.83M
2
Bank of America
Bank of America
North Carolina
+$4.86M
3
RI
RTW Investments
New York
+$4.77M
4
SCM
Sio Capital Management
New York
+$3.77M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$3.68M

Top Sellers

1
EC
EcoR1 Capital
California
-$17M
2
HF
HRT Financial
New York
-$6.43M
3
Millennium Management
Millennium Management
New York
-$6.13M
4
Aberdeen Group
Aberdeen Group
United Kingdom
-$5.23M
5
PA
Perceptive Advisors
New York
-$4.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
26
Walleye Capital
New York
$2.43M +$1.21M +297,166 +103%
Citadel Advisors
27
Citadel Advisors
Florida
$2.35M -$23.3K -5,742 -1%
EAM
28
Everstar Asset Management
North Carolina
$2.3M +$846K +208,381 +60%
Goldman Sachs
29
Goldman Sachs
New York
$1.94M -$1.8M -442,297 -49%
UBS Group
30
UBS Group
Switzerland
$1.93M +$681K +167,762 +57%
BCL
31
Bracebridge Capital LLC
Massachusetts
$1.91M – – –
DCM
32
DAFNA Capital Management
California
$1.53M -$30.4K -7,500 -2%
Stifel Financial
33
Stifel Financial
Missouri
$1.49M -$39.9K -9,825 -3%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$1.4M -$1.01M -249,614 -43%
DC
35
Diametric Capital
Massachusetts
$1.39M +$840K +206,967 +161%
Wellington Management Group
36
Wellington Management Group
Massachusetts
$1.2M +$77.5K +19,084 +7%
Point72 Asset Management
37
Point72 Asset Management
Connecticut
$1.18M +$1.15M +283,734 New
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$1.16M +$397K +97,776 +54%
AIC
39
AWM Investment Company
New York
$1.12M +$1.1M +270,400 New
Charles Schwab
40
Charles Schwab
California
$1.11M -$138K -34,102 -11%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$1.06M -$59.4K -14,636 -5%
N
42
Nuveen
North Carolina
$1.05M -$449K -110,551 -30%
RA
43
Rosalind Advisors
Ontario, Canada
$1.04M +$1.01M +250,000 New
Squarepoint
44
Squarepoint
New York
$1.04M +$1.01M +249,482 New
LI
45
Latash Investments
Alaska
$1.01M – – –
SAM
46
Simplify Asset Management
Nevada
$972K +$951K +234,279 New
Hudson Bay Capital Management
47
Hudson Bay Capital Management
Connecticut
$971K +$950K +234,000 New
Russell Investments Group
48
Russell Investments Group
United Kingdom
$939K +$67.9K +16,733 +8%
Creative Planning
49
Creative Planning
Kansas
$760K +$147K +36,217 +25%
AllianceBernstein
50
AllianceBernstein
Tennessee
$594K – – –
1
2
3 4 5

AQST Hedge Fund Activity: Q1 2026 in Review

179 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2026, worth a combined $298M — down 36% from $466M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new AQST positions and 43 closed out — a net gain of 6 holders — while 56 added to existing stakes and 47 trimmed.

The largest buyer was Balyasny Asset Management, adding an estimated $7.83M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $17M sold.

  • 179 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2026, up from 176 in Q4 2025.
  • Funds reported $298M of Aquestive Therapeutics stock for Q1 2026, down 36% quarter-over-quarter.
  • 49 funds opened new Aquestive Therapeutics positions in Q1 2026 and 43 closed out, a net change of +6 holders.
  • The largest Aquestive Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $7.83M added.
  • The largest Aquestive Therapeutics seller in Q1 2026 was EcoR1 Capital, an estimated $17M sold.

Based on aggregated 13F filings for Q1 2026.